000999 China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.
Closed 01-09 15:00:00
43.70
+0.17
+0.39%
High
44.40
Low
43.18
Vol
5.69M
Open
43.50
D1 Closing
43.53
Amplitude
2.80%
Mkt Cap
56.11B
Tradable Cap
55.76B
Total Shares
1.28B
T/O
249.00M
T/O Rate
0.45%
Tradable Shares
1.28B
P/B
2.72
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
China Resources Sanjiu Medical & Pharmaceutical Negotiates Inclusion of Two Products in Medical Insurance Catalog
MT Newswires Live · 2024-11-29
China Resources Sanjiu Medical & Pharmaceutical Negotiates Inclusion of Two Products in Medical Insurance Catalog
CR Sanjiu's Nine-Month Profit Increases
MT Newswires Live · 2024-10-28
CR Sanjiu's Nine-Month Profit Increases
China Resources Sanjiu Medical & Pharma Q3 Net Profit up 6.9% Y/Y
THOMSON REUTERS · 2024-10-25
China Resources Sanjiu Medical & Pharma Q3 Net Profit up 6.9% Y/Y
DIARY-China corporate earnings week ahead
Reuters · 2024-10-11
DIARY-China corporate earnings week ahead
CR Sanjiu's H1 Profit Jumps 28% on Higher Revenue
MT Newswires Live · 2024-08-26
CR Sanjiu's H1 Profit Jumps 28% on Higher Revenue
CR Sanjiu's H1 Profit Jumps 28% on Higher Revenue
MT Newswires Live · 2024-08-26
CR Sanjiu's H1 Profit Jumps 28% on Higher Revenue
BRIEF-China Resources Sanjiu's H1 Net Profit Up 27.8% Y/Y
Reuters · 2024-08-23
BRIEF-China Resources Sanjiu's H1 Net Profit Up 27.8% Y/Y
China Resources Sanjiu H1 Net Profit up 27.8% Y/Y
THOMSON REUTERS · 2024-08-23
China Resources Sanjiu H1 Net Profit up 27.8% Y/Y
CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%
MT Newswires Live · 2024-08-06
CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%
CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%
MT Newswires Live · 2024-08-06
CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%
China Resources Pharmaceutical Group's Subsidiary to Purchase 28% Interest in Tasly Pharmaceuticals
MT Newswires Live · 2024-08-05
China Resources Pharmaceutical Group's Subsidiary to Purchase 28% Interest in Tasly Pharmaceuticals
Tasly Pharmaceutical Says Trading in Shares to Resume on Aug 5
THOMSON REUTERS · 2024-08-04
Tasly Pharmaceutical Says Trading in Shares to Resume on Aug 5
BRIEF-China Resources Sanjiu To Become Tasly's Controlling Shareholder
Reuters · 2024-08-04
BRIEF-China Resources Sanjiu To Become Tasly's Controlling Shareholder
Tasly Pharmaceutical Says Controlling Shareholder, Parties Acting in Concert Agree to Sell 28% Stake in the Company to China Resources Sanjiu Medical for 6.2 Bln Yuan
THOMSON REUTERS · 2024-08-04
Tasly Pharmaceutical Says Controlling Shareholder, Parties Acting in Concert Agree to Sell 28% Stake in the Company to China Resources Sanjiu Medical for 6.2 Bln Yuan
China Resources Sanjiu, National Development Bank Ink Financial Services Deal
MT Newswires Live · 2024-07-30
China Resources Sanjiu, National Development Bank Ink Financial Services Deal
China Resources Sanjiu, National Development Bank Ink Financial Services Deal
MT Newswires Live · 2024-07-30
China Resources Sanjiu, National Development Bank Ink Financial Services Deal
Introduction
Company Name.
华润三九医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-03-09
Main Business:
华润三九医药股份有限公司主要从事医药产品的研发、生产、销售及相关健康服务。主要产品包括999感冒灵、999皮炎平、参附注射液、注射用头孢、免煎中药、三九胃泰颗粒、正天丸等。“999”主品牌在消费者和医药行业中均享有较高的认可度,多次被评为“中国最高认知率商标”、“中国最有价值品牌”。2021年公司拥有年销售额过亿元的品种23个,在2021年度中国非处方药产品综合统计排名中,“999感冒灵”和“999复方感冒灵”位居中成药感冒咳嗽类的第一名和第二名,“三九胃泰”位居中成药消化类第六名,“999皮炎平(红)”位居化学药皮肤科类第二名,“澳诺钙”位居化学药矿物质类第二名,“易善复”位居化学药消化类第二名。以公司产品“参附注射液”,“红花注射液”、“参麦注射液”,“血塞通软胶囊(理洫王)”为研究对象的科研项目先后荣获国家科学技术进步奖二等奖。
Issue price:
8.45
{"stockData":{"symbol":"000999","market":"SZ","secType":"STK","nameCN":"China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.","latestPrice":43.7,"timestamp":1736406225000,"preClose":43.53,"halted":0,"volume":5693784,"delay":0,"changeRate":0.0039,"floatShares":1276000000,"shares":1284000000,"eps":2.6553,"marketStatus":"Closed","change":0.17,"latestTime":"01-09 15:00:00","open":43.5,"high":44.4,"low":43.18,"amount":249000000,"amplitude":0.028,"askPrice":43.73,"askSize":5,"bidPrice":43.7,"bidSize":64,"shortable":0,"etf":0,"ttmEps":2.6553,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736472600000},"marketStatusCode":5,"adr":0,"adjPreClose":43.53,"symbolType":"stock","openAndCloseTimeList":[[1736386200000,1736393400000],[1736398800000,1736406000000]],"highLimit":47.88,"lowLimit":39.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1284298685,"isCdr":false,"pbRate":2.72,"roa":"--","peRate":16.457651,"roe":"14.99%","epsLYR":2.9,"committee":0.875556,"marketValue":56124000000,"turnoverRate":0.0045,"status":0,"floatMarketCap":55746000000},"requestUrl":"/m/hq/s/000999/wiki","defaultTab":"wiki","newsList":[{"id":"2487030403","title":"China Resources Sanjiu Medical & Pharmaceutical Negotiates Inclusion of Two Products in Medical Insurance Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2487030403","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487030403?lang=en_us&edition=fundamental","pubTime":"2024-11-29 11:47","pubTimestamp":1732852029,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu Medical & Pharmaceutical negotiated the inclusion of its products in the National Medical Insurance Catalog.These products are Chinese medicine Wenjing decoction granules and antibiotic cefoperazone sodium for injection, according to a Friday filing with the Shenzhen bourse.The drugs' inclusion is valid until Dec. 31, 2026.Shares of the drug company rose less than 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0010","BK0175","BK0183","BK0028","BK0239","BK0188","BK0012","BK0060","BK0196","000999","BK0185"],"gpt_icon":0},{"id":"2478125110","title":"CR Sanjiu's Nine-Month Profit Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2478125110","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478125110?lang=en_us&edition=fundamental","pubTime":"2024-10-28 14:22","pubTimestamp":1730096568,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu Medical & Pharmaceutical attributable profit rose to 3.24 billion yuan in the nine months through Sept. 30 from 2.70 billion yuan in the year-ago period.Revenue at the drug company grew to 19.7 billion yuan from 18.6 billion yuan a year earlier, according to a Friday filing by parent China Resources Pharmaceutical with the Hong Kong Exchange.Shares slid 2% during Monday's trading.Price : $46.52, Change: $-0.92, Percent Change: -1.94%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000999","BK0185","BK0188","BK4023","BK1570","BK0060","BK4585","BK0239","BK0196","BK0175","HKD","BK1191","BK4161","03320","BK0028","BK4526","BK0010","BK4588","BK0012","CR","BK0183"],"gpt_icon":0},{"id":"2478198439","title":"China Resources Sanjiu Medical & Pharma Q3 Net Profit up 6.9% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2478198439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478198439?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:31","pubTimestamp":1729859471,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nL4N3M113W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","BK0185","BK0028","BK0012","BK0183","000999","BK0175","BK0188","BK0010","BK0196","BK0239"],"gpt_icon":0},{"id":"2474833033","title":"DIARY-China corporate earnings week ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2474833033","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474833033?lang=en_us&edition=fundamental","pubTime":"2024-10-11 12:00","pubTimestamp":1728619200,"startTime":"0","endTime":"0","summary":"Oct 11 (Reuters) - Diary of China (.CSI300) corporate earnings for the week ahead. CHINA EARNINGS Company Event NameStart Date ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0070","BK0028","BK0030","BK0276","BK0060","BK0155","BK0214","000999","BK0183","BK0122","BK0197","BK0010","000938","BK0201","BK0018","BK0111","BK0182","BK0229","000776","BK0185","002841","BK0239","BK0103","BK0188","BK0196","BK0175","000792"],"gpt_icon":0},{"id":"2462495902","title":"CR Sanjiu's H1 Profit Jumps 28% on Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2462495902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462495902?lang=en_us&edition=fundamental","pubTime":"2024-08-26 15:15","pubTimestamp":1724656518,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["HKD","BK4585","BK4023","BK4588","BK1191","BK0239","CR","BK0060","BK4161","BK0010","BK0175","000999","BK0196","BK1570","SHE","03320","BK0183","BK0185","BK0188","BK0012","BK0028","BK4526"],"gpt_icon":0},{"id":"2462285959","title":"CR Sanjiu's H1 Profit Jumps 28% on Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2462285959","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462285959?lang=en_us&edition=fundamental","pubTime":"2024-08-26 15:15","pubTimestamp":1724656518,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu Medical & Pharmaceutical's attributable profit rose 28% to 2.40 billion yuan in the first half from 1.88 billion yuan in the year-ago period.Earnings per share at the drug company increased 27% to 1.87 yuan from 1.47 yuan in the previous year, according to a Friday filing by parent China Resources Pharmaceutical with the Hong Kong Stock Exchange.Revenue grew 7.3% to 14.11 billion yuan from 13.15 billion yuan a year earlier.CR Sanjiu's shares rose nearly 3% in recent trading.Price : $43.95, Change: $+1.2, Percent Change: +2.86%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CR","03320","000999"],"gpt_icon":0},{"id":"2461560636","title":"BRIEF-China Resources Sanjiu's H1 Net Profit Up 27.8% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2461560636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461560636?lang=en_us&edition=fundamental","pubTime":"2024-08-23 19:54","pubTimestamp":1724414053,"startTime":"0","endTime":"0","summary":"Aug 23 (Reuters) - China Resources Sanjiu Medical & Pharmaceutical Co Ltd : * H1 NET PROFIT UP 27.8% Y/Y Source text Further company coverage: (Reporting by Beijing Newsroom)((Ethan.Wang@thomsonreuters.com;))","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0175","BK0028","000999","BK0239","BK0196","BK0010","BK0185","BK0012","BK0183","BK0188"],"gpt_icon":0},{"id":"2461560369","title":"China Resources Sanjiu H1 Net Profit up 27.8% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2461560369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461560369?lang=en_us&edition=fundamental","pubTime":"2024-08-23 19:54","pubTimestamp":1724414053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240823:nL4N3KA0VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0012","000999","BK0183","BK0028","BK0239","BK0010","BK0060","BK0188","BK0196","BK0185","BK0175"],"gpt_icon":0},{"id":"2457068648","title":"CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457068648","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457068648?lang=en_us&edition=fundamental","pubTime":"2024-08-06 12:47","pubTimestamp":1722919671,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu Medical and Pharmaceutical plans to acquire a 28% stake in its local peer Tasly Pharmaceutical for 6.21 billion yuan, according to a Sunday filing on the Shenzhen Stock Exchange.CR Sanjiu will buy the stake from Tasly Great Health Industry Investment Group or Tasly Group and six other investors, which are all limited partnerships.Tasly Group also committed to transferring 5% of Tasly's shares to CR Sanjiu's shareholder, Guoxin Investment, after the registration date, the filing noted.Tasly's shares dropped more than 4% in recent trade in Shanghai, while CR Sanjiu's shares were marginally down in Shenzhen.Price : 42.17, Change: -0.17, Percent Change: -0.40%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0010","BK0185","CR","BK0188","BK0175","BK4161","BK0196","BK0183","BK0028","000999","600535","BK0012","BK0239"],"gpt_icon":0},{"id":"2457068455","title":"CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457068455","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457068455?lang=en_us&edition=fundamental","pubTime":"2024-08-06 12:47","pubTimestamp":1722919671,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["CR","BK0239","BK0028","BK0010","BK0175","000999","600535","BK0196","BK4161","BK0060","BK0183","BK0185","SHE","BK0188","BK0012"],"gpt_icon":0},{"id":"2457314741","title":"China Resources Pharmaceutical Group's Subsidiary to Purchase 28% Interest in Tasly Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2457314741","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457314741?lang=en_us&edition=fundamental","pubTime":"2024-08-05 17:35","pubTimestamp":1722850557,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK1191","BK0183","SHE","BK0175","BK0196","03320","BK0060","000999","BK0185","BK0188","BK0010","BK1570","BK0028","600535","BK0012","BK0239"],"gpt_icon":0},{"id":"2456782555","title":"Tasly Pharmaceutical Says Trading in Shares to Resume on Aug 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2456782555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456782555?lang=en_us&edition=fundamental","pubTime":"2024-08-04 15:49","pubTimestamp":1722757794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240804:nL4N3JR01B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","BK0175","BK0028","000999","600535","BK0239","BK0196","BK0010","BK0185","BK0012","BK0183","BK0188"],"gpt_icon":0},{"id":"2456782435","title":"BRIEF-China Resources Sanjiu To Become Tasly's Controlling Shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2456782435","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456782435?lang=en_us&edition=fundamental","pubTime":"2024-08-04 15:49","pubTimestamp":1722757794,"startTime":"0","endTime":"0","summary":"Aug 4 - Tasly Pharmaceutical Group Co Ltd : * SAYS CONTROLLING SHAREHOLDER, PARTIES ACTING IN CONCERT AGREE TO SELL 28% STAKE IN THE COMPANY TO CHINA RESOURCES SANJIU MEDICAL FOR 6.2 BILLION YUAN * SAYS CONTROLLING SHAREHOLDER WILL CHANGE TO CHINA RESOURCES SANJIU, ACTUAL CONTROLLER WILL BE CHINA RESOURCES AFTER STAKE TRANSFER * SAYS TRADING IN SHARES TO RESUME ON AUG 5 Source text 1 Source text 2 Further company coverage: ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0010","BK0196","BK0175","BK0028","BK0185","000999","BK0060","BK0012","BK0188","BK0183"],"gpt_icon":0},{"id":"2456778253","title":"Tasly Pharmaceutical Says Controlling Shareholder, Parties Acting in Concert Agree to Sell 28% Stake in the Company to China Resources Sanjiu Medical for 6.2 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2456778253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456778253?lang=en_us&edition=fundamental","pubTime":"2024-08-04 15:47","pubTimestamp":1722757643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240804:nL4N3JR01B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4231","BK0060","BK0010","BK0185","BK0188","BK0175","BK4080","BK0196","BK0183","BK0028","ADC","000999","600535","BK0012","BK0239"],"gpt_icon":0},{"id":"2455967580","title":"China Resources Sanjiu, National Development Bank Ink Financial Services Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2455967580","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455967580?lang=en_us&edition=fundamental","pubTime":"2024-07-30 12:48","pubTimestamp":1722314911,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["000999","BK0010","BK0185","BK0188","BK0012","BK0196","BK0060","NHLD","BK0183","BK0175","SHE","BK0239","BK0028"],"gpt_icon":0},{"id":"2455067589","title":"China Resources Sanjiu, National Development Bank Ink Financial Services Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2455067589","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455067589?lang=en_us&edition=fundamental","pubTime":"2024-07-30 12:48","pubTimestamp":1722314911,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu Medical and Pharmaceutical signed a financial services agreement with the Shenzhen branch of the China Development Bank, according to a filing on the Shenzhen Stock Exchange.The lender will provide financial product services, such as loans, debt, leases and securities, for the pharmaceutical company's various projects. The financial services to be provided will be up to 10 billion yuan.The agreement is valid for five years, the Monday filing added.Shares of the company slid more than 1% in recent trade.Price : 40.07, Change: -0.52, Percent Change: -1.28%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0175","BK0196","BK0060","BK0188","000999","BK0010","BK0028","BK0185","BK0012","NHLD","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-03-09","address":"广东省深圳市龙华区观湖街道观澜高新园区观清路1号","stockEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0259},{"period":"3month","weight":-0.0594},{"period":"6month","weight":0.0866},{"period":"1year","weight":0.1952},{"period":"ytd","weight":-0.0144}],"companyName":"华润三九医药股份有限公司","boardCode":"AI0027","perCapita":"24434股","boardName":"医药制造业","registeredCapital":"128429万元","compareEarnings":[{"period":"1week","weight":-0.0157},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.002},{"period":"6month","weight":0.0808},{"period":"1year","weight":0.116},{"period":"ytd","weight":-0.0419}],"survey":" 华润三九医药股份有限公司主要从事医药产品的研发、生产、销售及相关健康服务。主要产品包括999感冒灵、999皮炎平、参附注射液、注射用头孢、免煎中药、三九胃泰颗粒、正天丸等。“999”主品牌在消费者和医药行业中均享有较高的认可度,多次被评为“中国最高认知率商标”、“中国最有价值品牌”。2021年公司拥有年销售额过亿元的品种23个,在2021年度中国非处方药产品综合统计排名中,“999感冒灵”和“999复方感冒灵”位居中成药感冒咳嗽类的第一名和第二名,“三九胃泰”位居中成药消化类第六名,“999皮炎平(红)”位居化学药皮肤科类第二名,“澳诺钙”位居化学药矿物质类第二名,“易善复”位居化学药消化类第二名。以公司产品“参附注射液”,“红花注射液”、“参麦注射液”,“血塞通软胶囊(理洫王)”为研究对象的科研项目先后荣获国家科学技术进步奖二等奖。","serverTime":1736465235968,"listedPrice":8.45,"stockholders":"52207人(较上一季度增加3.45%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.(000999),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.(000999) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.,000999,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票老虎,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票老虎国际,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.行情,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票行情,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股价,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股市,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票价格,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票交易,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票购买,China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.(000999),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest China Resources Sanjiu Medical&Pharmaceutical Co.,Ltd.(000999) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}